Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 5, 2026, 7:00 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–44 of 44 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: fluticasone propionate (FP) Clear all

Conditions: Asthma
Interventions: Fluticasone furoate/ Vilanterol 100 mcg/25 mcg, Fluticasone propionate 250 mcg, Placebo via ELLIPTA inhaler, Placebo via DISKUS / ACCUHALER; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 12 Years to 50 Years
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 13
States / cities: Huntington Beach, California • Los Angeles, California • San Diego, California + 9 more

Conditions: Asthma
Interventions: Fluticasone Propionate/salmeterol xinofoate 250/50 mcg BID, Fluticasone propionate 250 mcg BID; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 12 Years and older
Enrollment: 628 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 58
States / cities: Birmingham, Alabama • Mobile, Alabama • Fresno, California + 54 more

Conditions: Asthma
Interventions: Fp MDPI, Flovent Diskus, albuterol/salbutamol, Placebo MDPI; Drug
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.; Industry
Eligibility: 12 Years and older
Enrollment: 909 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 129
States / cities: Homewood, Alabama • Goodyear, Arizona • Scottsdale, Arizona + 104 more

Conditions: Perennial Allergic Rhinitis, Allergic Rhinitis, Hay Fever
Interventions: Ciclesonide; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 106 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005
U.S. locations: 1
States / cities: Long Beach, California

Conditions: Asthma
Interventions: Fp/ABS, FP, ABS, Placebo; Drug
Lead sponsor: Teva Branded Pharmaceutical Products R&D LLC; Industry
Eligibility: 12 Years and older
Enrollment: 724 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 91
States / cities: Phoenix, Arizona • Tucson, Arizona • Little Rock, Arkansas + 73 more

Conditions: Asthma
Interventions: TEV-56248, Fp MDPI; Drug
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.; Industry
Eligibility: 4 Years to 11 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024
U.S. locations: 10
States / cities: Mobile, Alabama • Long Beach, California • Miami, Florida + 5 more

Conditions: Asthma
Interventions: HFA FP MDI; Drug
Lead sponsor: University of Florida; Other
Eligibility: 1 Year to 18 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2004
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Bronchospasm, Activity/Exercise Induced Bronchospasm
Interventions: Fluticasone propionate/salmeterol, Fluticasone Propionate; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 4 Years to 17 Years
Enrollment: 248 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2006
U.S. locations: 50
States / cities: Little Rock, Arkansas • Huntington Beach, California • Orange, California + 45 more

Conditions: Asthma
Interventions: FP 100, GSK2190915 100, GSK2190915 300, montelukast, placebo, FP/SAL 100/50; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 12 Years and older · Female only
Enrollment: 162 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 32
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Huntington Beach, California + 28 more

Conditions: Persistent Asthma
Interventions: Fp MDPI, FS MDPI, FLOVENT HFA, ADVAIR DISKUS, albuterol/salbutamol HFA; Drug
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.; Industry
Eligibility: 12 Years and older
Enrollment: 758 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 101
States / cities: Birmingham, Alabama • Mobile, Alabama • Pell City, Alabama + 85 more

Conditions: Asthma
Interventions: Treatment A: Fp MDPI, Treatment B: FS MDPI, Treatment C Flovent, Treatment D: Advair; Drug
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.; Industry
Eligibility: 12 Years and older
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015
U.S. locations: 3
States / cities: Raleigh, North Carolina • Edmond, Oklahoma • San Antonio, Texas

Conditions: Asthma, COPD
Interventions: MGR001, Advair® Diskus®, Seretide™ Accuhaler™; Drug
Lead sponsor: Mylan Pharma UK Ltd.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Asthma
Interventions: ADVAIR 100/50mcg, ADVAIR 250/50mcg, FLOVENT 100mcg, FLOVENT 250mcg; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 4 Years to 11 Years
Enrollment: 6,250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 267
States / cities: Birmingham, Alabama • Mobile, Alabama • Montgomery, Alabama + 208 more

Conditions: Asthma
Interventions: fluticasone propionate/salmeterol (Flu/Sal) : 100mcg/50mcg, 250mcg/50mcg,500mcg/50 mcg; Drug
Lead sponsor: Sandoz; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009
U.S. locations: 3
States / cities: Gainesville, Florida • Iowa City, Iowa • Madison, Wisconsin

Conditions: Asthma
Interventions: Fluticasone Propionate, Water Mouthwash, EVOOW Mouthwash; Drug · Other
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Asthma
Interventions: Fluticasone Propionate (FP); Drug
Lead sponsor: Dey; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 498 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Rock Hill, South Carolina

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: fluticasone and salmeterol; Drug
Lead sponsor: University of Chicago; Other
Eligibility: 50 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Chronic Obstructive Pulmonary Disease
Interventions: Fluticasone Propionate/Formoterol Fumarate, Fluticasone Propionate, Formoterol Fumarate, Fluticasone Propionate/Salmeterol Xinafoate, Placebo; Drug
Lead sponsor: Dey; Industry
Eligibility: 40 Years and older
Enrollment: 457 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 49
States / cities: Birmingham, Alabama • Jasper, Alabama • Phoenix, Arizona + 44 more

Conditions: Asthma
Interventions: Fluticasone Furoate/Vilanterol 100/25 mcg via ELLIPTA inhaler, Placebo inhalation powders via ELLIPTA inhaler, Fluticasone Propionate/Salmeterol 250/50 mcg via ACCUHALER/DISKUS inhaler, Placebo inhalation powder via ACCUHALER/DISKUS inhaler, Fluticasone Propionate 250 mcg via ACCUHALER/DISKUS inhaler; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 12 Years and older
Enrollment: 1,526 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 34
States / cities: Huntington Beach, California • Riverside, California • Rolling Hills Estates, California + 30 more

Conditions: Asthma
Interventions: fluticasone propionate/salmeterol (FSC), montelukast (MON), fluticasone propionate (FP), placebo nasal, ADVAIR DISKUS, placebo capsule, placebo DISKUS; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 15 Years and older
Enrollment: 725 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 104
States / cities: Birmingham, Alabama • Glendale, Arizona • Scottsdale, Arizona + 88 more

Search by objective public record fields.

Crossover Study Comparing Fluticasone Furoate (FF)/Vilanterol (VI) Once Daily Versus Fluticasone Propionate (FP) Twice Daily in Subjects With Asthma and Exercise-Induced Bronchoconstriction (EIB)

A 12-Month Study Comparing Fluticasone Propionate/Salmeterol (ADVAIR) DISKUS Combination Product 250/50mcg Twice Daily To Fluticasone Propionate (FLOVENT) DISKUS 250 mcg Twice Daily In Symptomatic Patients With Asthma

A Study of the Effectiveness and Safety of Different Doses of Fluticasone Propionate Taken From a Dry Powder Inhaler in Adolescents and Adults Who Have Asthma That is Not Controlled by Asthma Medications Not Containing Steroids

Safety of Ciclesonide Nasal Spray Administered With Inhaled Fluticasone Dipropionate/Salmeterol in Adults With Perennial Allergic Rhinitis (BY9010/M1-409)

A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma

Pharmacokinetic Profile and Safety of Fluticasone Propionate and Albuterol Sulfate in Combination When Compared to Fluticasone Propionate Multidose Dry Powder Inhaler (Fp MDPI) in Children Aged 4 to 11 Years Old

Effect of Age and Device on Delivery of Fluticasone

A Study Measuring Asthma Control In Pediatric And Adolescent Subjects Whose Asthma Is Worsened By Activity Or Exercise

Safety and Efficacy Study of Adding GSK2190915 to Low Dose Inhaled Corticosteroid Treatment for Asthma Subjects > or = 12 Years of Age

Long-Term Safety Study of Fluticasone Propionate (Fp) Multidose Dry Powder Inhaler (MDPI) and Fluticasone Propionate/Salmeterol (FS) MDPI in Patients With Persistent Asthma

Study to Determine the Pharmacokinetics and Tolerability of Fluticasone Propionate MDPI and Fluticasone Propionate/Salmeterol MDPI Compared to High Strength FLOVENT® DISKUS® and ADVAIR® DISKUS® in Patients With Persistent Asthma 12 Years of Age and Older

Bioequivalence Study to Assess Systemic Exposure of FP and SAL FDC From Different DPIs

6-month Safety and Benefit Study of ADVAIR in Children 4-11 Years Old

Pilot Study to Examine the Post-Dose Changes in Exhaled Nitric Oxide (eNO) Following Treatment With Fluticasone Propionate (FP)/Salmeterol (SAL) Combination Product Advair

Novel Method for Removal of Orally Deposited Inhaled Fluticasone Propionate

A 12-Week Study in Adult Subjects With Asthma

A Pilot Study of the Mechanism of Synergism Between FP and Salmeterol in Preventing COPD Exacerbations

A Dose-Finding Study Evaluating Safety and Efficacy in Patients With Chronic Obstructive Pulmonary Disease

An Efficacy and Safety Study of Fluticasone Furoate/Vilanterol 100/25 Microgram (mcg) Inhalation Powder, Fluticasone Propionate/Salmeterol 250/50 mcg Inhalation Powder, and Fluticasone Propionate 250 mcg Inhalation Powder in Adults and Adolescents With Persistent Asthma

Study Of Allergic Rhinitis In Patients Who Also Have Asthma